Algert Global’s Fulcrum Therapeutics FULC Stock Holding History

Algert Global’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$371K	Buy	101,360 +68,310	+207%	+$416K	﹤0.01%	1111
2026 Q1	$253K	Buy	+33,050	New	+$307K	﹤0.01%	1047
2025 Q4	–	Sell	-16,550	Closed	-$152K	–	1207
2025 Q3	$152K	Buy	+16,550	New	+$120K	﹤0.01%	1063
2025 Q2	–	Sell	-36,147	Closed	-$104K	–	1227
2025 Q1	$104K	Buy	36,147 +2,030	+6%	+$7.46K	﹤0.01%	1130
2024 Q4	$160K	Sell	34,117 -5,570	-14%	-$20.5K	﹤0.01%	1094
2024 Q3	$142K	Sell	39,687 -1,616	-4%	-$12K	﹤0.01%	1091
2024 Q2	$256K	Buy	41,303 +27,633	+202%	+$209K	0.01%	1182
2024 Q1	$129K	Sell	13,670 -12,160	-47%	-$109K	0.01%	996
2023 Q4	$174K	Sell	25,830 -5,180	-17%	-$23K	0.01%	1038
2023 Q3	$138K	Buy	+31,010	New	+$136K	0.01%	1008

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Algert Global's FULC Position: Q2 2026 in Review

Algert Global increased its Fulcrum Therapeutics (FULC) stake by 207% in Q2 2026, buying an estimated $416K and bringing the position to 101,360 shares worth $371K. The position accounts for ﹤0.01% of the portfolio, ranked #1111.

Algert Global first reported a position in FULC in Q3 2023 and has held it in 10 quarters since. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

Algert Global held 101,360 shares of Fulcrum Therapeutics worth $371K as of Q2 2026.
Algert Global bought 68,310 Fulcrum Therapeutics shares in Q2 2026, an estimated $416K.
Fulcrum Therapeutics made up ﹤0.01% of Algert Global's portfolio in Q2 2026, its #1111 holding.
Algert Global first reported a position in Fulcrum Therapeutics in Q3 2023 and has held it in 10 quarters since.
155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.